Free tool
FAERS Monitor: Opdivo
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming BLA 125527 or its brand name (Opdivo, Nivolumab). Reports on generic versions are filed under their own applications.
Reports
97,932
Serious
87,480
89% of reports
Hospitalization
39,754
Death reported
25,065
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- death12,098
- malignant neoplasm progression9,963
- off label use6,485
- diarrhoea5,336
- fatigue4,264
- pyrexia3,792
- intentional product use issue3,329
- nausea3,233
- rash3,143
- decreased appetite2,949
- dyspnoea2,709
- pneumonia2,499
- colitis2,300
- pneumonitis2,219
- hypothyroidism2,155
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2011 | 1 |
| 2012 | 5 |
| 2013 | 41 |
| 2014 | 140 |
| 2015 | 2,615 |
| 2016 | 7,163 |
| 2017 | 9,632 |
| 2018 | 10,908 |
| 2019 | 11,341 |
| 2020 | 8,904 |
| 2021 | 9,407 |
| 2022 | 10,069 |
| 2023 | 7,721 |
| 2024 | 7,628 |
| 2025 | 6,915 |
| 2026 | 5,442 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 20,956,227 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| malignant neoplasm progressionSignal | 9,963 | 23.0 | 22.6 | 190,509 |
| pneumonitisSignal | 2,219 | 19.0 | 18.2 | 34,714 |
| hypothyroidismSignal | 2,155 | 15.5 | 14.8 | 27,230 |
| colitisSignal | 2,300 | 13.8 | 13.2 | 25,698 |
| intentional product use issueSignal | 3,329 | 8.4 | 8.2 | 21,098 |
| deathSignal | 12,098 | 3.0 | 3.0 | 17,076 |
| decreased appetiteSignal | 2,949 | 2.7 | 2.7 | 3,274 |
| pyrexiaSignal | 3,792 | 2.4 | 2.3 | 3,014 |
| diarrhoea | 5,336 | 1.8 | 1.7 | 1,872 |
| pneumonia | 2,499 | 1.7 | 1.6 | 665 |
| off label use | 6,485 | 1.6 | 1.6 | 1,490 |
| rash | 3,143 | 1.6 | 1.5 | 626 |
| fatigue | 4,264 | 1.2 | 1.1 | 117 |
| dyspnoea | 2,709 | 1.0 | 1.0 | 2 |
| nausea | 3,233 | 0.9 | 0.8 | 58 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.